EGFR and lung adenocarcinoma: However, survival analysis of only lung adenocarcinoma patients with EGFR-non-mutated status identified poorer overall survival (statistically significant at p≤0.005) with higher MEOX2 and GLI-1 protein co-expression levels (p=0.045 and p=0.006, respectively) (Figure 9D).